(Q37679919)

21 August 2017

1 reference

title

Alemtuzumab and multiple sclerosis: therapeutic application (English)

1 reference

21 August 2017

0 references

Mohammad Ali Sahraian

object named as

Mohammad Ali Sahraian

series ordinal

3

0 references

Robert Zivadinov

series ordinal

4

object named as

Robert Zivadinov

1 reference

21 August 2017

Alireza Minagar

1

1 reference

21 August 2017

J Steven Alexander

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

421-429

1 reference

Multiple sclerosis--the plaque and its pathogenesis

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Immunology of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Blood-brain barrier disruption in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Immunologic mechanisms of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Immunological update on multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Multiple sclerosis: a complicated picture of autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

IL-17 family cytokines and the expanding diversity of effector T cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

"Infectious" transplantation tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Recognition of CD52 allelic gene products by CAMPATH-1H antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Cd52, known as a major maturation-associated sperm membrane antigen secreted from the epididymis, is not required for fertilization in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Induction of tolerance by monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Melanoma following treatment with alemtuzumab for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003586806

10.1517/14712591003586806

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference